Image source: Shutterstock

Highlights

Orthocell’s Remplir™ nerve repair product receives regulatory approval in Hong Kong, allowing immediate market entry.

The total addressable market (TAM) across approved jurisdictions now stands at US$1.8 billion, with further expansion into the EU and UK planned within 6–12 months.

Company maintains cash reserves of $31.7 million, supporting a broad international rollout strategy.

Orthocell Ltd (ASX:OCC) continues to boost its global footprint with the latest regulatory milestone for its flagship nerve repair device, Remplir™, securing approval from Hong Kong’s Department of Health Medical Device Division. The greenlight allows Orthocell to officially commence sales in the strategically significant Hong Kong market—widely recognised as a leading medical hub within Asia and the APEC region.

Remplir™ is a collagen-based wrap used in nerve repair surgeries to aid surgeons in the regeneration of damaged nerves, enhancing post-operative outcomes. The early approval—granted just one month after submission on April 10—was originally expected in Q4 2025, and highlights both the product’s clinical quality and growing global recognition of the Orthocell brand.

Strategic Access to Asia’s Medical Nerve Repair Market

With Hong Kong’s inclusion, Orthocell has now secured approvals for Remplir in Australia, New Zealand, Singapore, Thailand, the US, and Canada. These approved regions together represent a total addressable market of US$1.8 billion, nearly half of the US$3.5 billion global TAM the company is targeting.

Orthocell views Hong Kong not just as a standalone opportunity, but as a gateway to broader Asia-Pacific market access, offering proximity to key medical institutions, training hubs, and potential commercial partners. Plans are now underway to appoint a local specialist distributor, drawing on the company’s established expertise working with international partners for both Remplir and its dental regeneration product, Striate+.

Eyeing Further Expansion: EU and UK Next

Orthocell's near-term roadmap includes submitting regulatory applications in the EU and UK within the next 6 to 12 months, a move that would further extend Remplir’s commercial reach into lucrative European healthcare markets. These expansion efforts are strategically aligned with Orthocell’s broader commercial plan, which separates its focus between directly managing US sales—its largest single market worth US$1.6 billion—and using external distributors in secondary markets like Hong Kong.

Despite the expanding scope of operations, Orthocell emphasizes that minimal internal resource expansion is required outside of the US.